Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention. Many have produced outstanding returns over the past two years. Naturally, most investors want to cash in on this, but the biggest names in the industry tend to trade at steep premiums. It might be worth considering smaller, under-the-radar AI-focused companies that haven't performed well yet but boast significant upside potential.And some think that description fits Recursion Pharmaceuticals (NASDAQ: RXRX), an AI-focused biotech company. The stock has attracted the attention of some of the most famous names in the investing world, including Cathie Wood, CEO of Ark Invest. But is Recursion Pharmaceuticals really worth investing in right now after shedding 35% of its value this year?Image source: Getty Images.Continue reading
Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention. Many have produced outstanding returns over the past two years. Naturally, most investors want to cash in on this, but the biggest names in the industry tend to trade at steep premiums. It might be worth considering smaller, under-the-radar AI-focused companies that haven't performed well yet but boast significant upside potential.
And some think that description fits Recursion Pharmaceuticals (NASDAQ: RXRX), an AI-focused biotech company. The stock has attracted the attention of some of the most famous names in the investing world, including Cathie Wood, CEO of Ark Invest. But is Recursion Pharmaceuticals really worth investing in right now after shedding 35% of its value this year?
Image source: Getty Images.
